AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company backed by EQT Life Sciences, closed 8.4% below its IPO price in its trading debut Friday after the firm raised $200 million in a listing.
EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO
📅 Published: February 9, 2026 |
📂 Category: Uncategorized
